138 related articles for article (PubMed ID: 30909182)
1. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
Laxmi A; Gupta P; Gupta J
Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
[TBL] [Abstract][Full Text] [Related]
3. Loss of CCDC6, the first identified RET partner gene, affects pH2AX S139 levels and accelerates mitotic entry upon DNA damage.
Merolla F; Luise C; Muller MT; Pacelli R; Fusco A; Celetti A
PLoS One; 2012; 7(5):e36177. PubMed ID: 22655027
[TBL] [Abstract][Full Text] [Related]
4. Identification of sumoylation sites in CCDC6, the first identified RET partner gene in papillary thyroid carcinoma, uncovers a mode of regulating CCDC6 function on CREB1 transcriptional activity.
Luise C; Merolla F; Leone V; Paladino S; Sarnataro D; Fusco A; Celetti A
PLoS One; 2012; 7(11):e49298. PubMed ID: 23145146
[TBL] [Abstract][Full Text] [Related]
5. CCDC6: the identity of a protein known to be partner in fusion.
Cerrato A; Merolla F; Morra F; Celetti A
Int J Cancer; 2018 Apr; 142(7):1300-1308. PubMed ID: 29044514
[TBL] [Abstract][Full Text] [Related]
6. Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
Leone V; Langella C; Esposito F; Arra C; Palma G; Rea D; Paciello O; Merolla F; De Biase D; Papparella S; Celetti A; Fusco A
Oncotarget; 2015 Jun; 6(17):15628-38. PubMed ID: 25970781
[TBL] [Abstract][Full Text] [Related]
7. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
[TBL] [Abstract][Full Text] [Related]
8. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L
Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662
[TBL] [Abstract][Full Text] [Related]
9. The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer.
Cerrato A; Visconti R; Celetti A
Mol Cancer; 2018 Feb; 17(1):46. PubMed ID: 29455670
[TBL] [Abstract][Full Text] [Related]
10. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
[TBL] [Abstract][Full Text] [Related]
11. Drosophila Cancer Models Identify Functional Differences between Ret Fusions.
Levinson S; Cagan RL
Cell Rep; 2016 Sep; 16(11):3052-3061. PubMed ID: 27626672
[TBL] [Abstract][Full Text] [Related]
12. FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells.
Zhao J; Tang J; Men W; Ren K
FEBS Lett; 2012 Dec; 586(24):4257-63. PubMed ID: 23108047
[TBL] [Abstract][Full Text] [Related]
13. Genetic fusions favor tumorigenesis through degron loss in oncogenes.
Liu J; Tokheim C; Lee JD; Gan W; North BJ; Liu XS; Pandolfi PP; Wei W
Nat Commun; 2021 Nov; 12(1):6704. PubMed ID: 34795215
[TBL] [Abstract][Full Text] [Related]
14. Role of proto-oncogene activation in carcinogenesis.
Anderson MW; Reynolds SH; You M; Maronpot RM
Environ Health Perspect; 1992 Nov; 98():13-24. PubMed ID: 1486840
[TBL] [Abstract][Full Text] [Related]
15. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
16. CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1.
Leone V; Mansueto G; Pierantoni GM; Tornincasa M; Merolla F; Cerrato A; Santoro M; Grieco M; Scaloni A; Celetti A; Fusco A
Oncogene; 2010 Jul; 29(30):4341-51. PubMed ID: 20498639
[TBL] [Abstract][Full Text] [Related]
17. Silencing of CCDC6 reduces the expression of 14-3-3σ in colorectal carcinoma cells.
Thanasopoulou A; Xanthopoulou AG; Anagnostopoulos AK; Konstantakou EG; Margaritis LH; Papassideri IS; Stravopodis DJ; Tsangaris GT; Anastasiadou E
Anticancer Res; 2012 Mar; 32(3):907-13. PubMed ID: 22399611
[TBL] [Abstract][Full Text] [Related]
18. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
[TBL] [Abstract][Full Text] [Related]
19. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of RET fusions in advanced colorectal cancer.
Le Rolle AF; Klempner SJ; Garrett CR; Seery T; Sanford EM; Balasubramanian S; Ross JS; Stephens PJ; Miller VA; Ali SM; Chiu VK
Oncotarget; 2015 Oct; 6(30):28929-37. PubMed ID: 26078337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
